The effects of rosuvastatin on cardiac function and serum soluble ST2 and Galectin-3 concentrations in hemodialysis patients

Objective To investigate the effects of rosuvastatin on cardiac function, lipid metabolism and serum soluble ST2 and Galectin-3 concentrations in hemodialysis patients. Methods Eighty patients who underwent hemodialysis from January 2018 to January 2019 were selected and randomly divided into control group and observation group. The control group received routine hemodialysis, the observation group used oral rosuvastatin treatment (20 mg, qd) lasting for 3 m on the basis of routine hemodialysis. The heart function, lipid metabolism, and serum soluble ST2, and Galectin-3 concentration before and after the treatment process were measured and compared between the two groups. Results The levels of cardiac output (CO) and Left Ventricular Ejection Fractions (LVEF) in the observation group were significantly higher than those before treatment, and statistically significantly higher than the control group (P<0.05).The serum concentrations of TG,LDL, TC and BUA in the observation group were significantly lower than the control group (P<0.05). The serum soluble ST2 and Galectin-3 levels in the observation group were significantly lower than those before treatment, and significantly lower than the control group, with the difference of statistical significance (P<0.05). No severe adverse reactions were observed in two groups of patients during the treatment course. Conclusions Rosuvastatin can improve the cardiac function of dialysis patients by improving lipid metabolism and lowering serum soluble ST2 and Galectin-3 concentrations, with high safety.